SCHEMBL4496248

SCHEMBL4496248

COC(=O)c1ccc2[nH]c(NCC3(F)CCNCC3)nc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 1/20 0.43
KDM4E B2RXH2 4/20 0.40
LMNA P02545 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
RHEB Q15382 1/20 0.36
HPGD P15428 2/20 0.36
PKM P14618 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4496242 0.99 CSNK1E (0.42) CSNK1EKDM4ELMNAALDH1A1HTT
Hydrochloric Acid SCHEMBL4496250 0.91 ALDH1A1 (0.49) CSNK1EKDM4ELMNAALDH1A1HTT
SCHEMBL4497494 0.82 PKM (0.44) CSNK1EPKM
SCHEMBL4490296 0.80 HDAC6 (0.46) LMNAALDH1A1HTTSMN1; SMN2MAPK1
SCHEMBL4501990 0.78 MEN1 (0.42) CSNK1EKDM4ELMNAALDH1A1HTT
SCHEMBL2671396 0.74 KDM4E (0.49) CSNK1EKDM4ELMNAALDH1A1HTT
SCHEMBL2759988 0.73 KDM4E (0.48) CSNK1EKDM4ELMNAALDH1A1HTT
SCHEMBL4501997 0.70 MEN1 (0.42) KDM4ELMNAALDH1A1HTTL3MBTL1
SCHEMBL4504235 0.70 PTGER4 (0.49) KDM4ELMNAALDH1A1HTTSMN1; SMN2
SCHEMBL1170648 0.70 KDM4E (0.61) KDM4ELMNAALDH1A1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524841-B2 4,4-disubstituted piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-28 US disclosed
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-15 US disclosed
EP-1505067-A1 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM TEIJIN LIMITED (JP) 2005-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells CCR3, CCR1, CCR4 CSNK1E 3504/4885KDM4E 3617/4885LMNA 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.